OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, Its Second Generation COVID-19 Vaccine
OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of CoVepiT, Its Second Generation COVID-19 Vaccine
12/18/20, 6:39 AM
Location
Money raised
€5.2 million
Regulatory News: